Glassman Wealth Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Glassman Wealth Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-152	Closed	-$24K	–	1830
2022 Q2	$24K	Buy	+152	New	+$23.4K	﹤0.01%	574
2020 Q4	–	Sell	-102	Closed	-$15K	–	1442
2020 Q3	$15K	Buy	+102	New	+$12.6K	﹤0.01%	510
2020 Q2	–	Sell	-6	Closed	-$1K	–	1381
2020 Q1	$1K	Buy	6 +3	+100%	+$388	﹤0.01%	905
2019 Q4	$0	Hold	3	–	–	﹤0.01%	1324
2019 Q3	$0	Sell	3 -1	-25%	-$134	﹤0.01%	1208
2019 Q2	$1K	Buy	4 +1	+33%	+$134	﹤0.01%	869
2019 Q1	$0	Buy	+3	New	+$391	﹤0.01%	1120

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Glassman Wealth Services's JAZZ Position: Q3 2022 in Review

Glassman Wealth Services sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 152 shares — an estimated $24K sold.

Glassman Wealth Services first reported a position in JAZZ in Q1 2019 and held it in 7 quarters. The position peaked at $24K in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

Glassman Wealth Services reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Glassman Wealth Services sold 152 Jazz Pharmaceuticals shares in Q3 2022, an estimated $24K.
Glassman Wealth Services first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 7 quarters.
Glassman Wealth Services's Jazz Pharmaceuticals position peaked at $24K in Q2 2022.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.